Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2009 Jun;204(2):321-9.
doi: 10.1016/j.atherosclerosis.2008.09.033. Epub 2008 Oct 9.

Osteoprotegerin, vascular calcification and atherosclerosis

Ann Van Campenhout  1 , Jonathan Golledge
Affiliations
Review

Osteoprotegerin, vascular calcification and atherosclerosis

Ann Van Campenhout et al. Atherosclerosis. 2009 Jun.

Abstract

The association of bone pathologies with atherosclerosis has stimulated the search for common mediators linking the skeletal and the vascular system. Since its initial discovery as a key regulator in bone metabolism, osteoprotegerin (OPG) has become the subject of intense interest for its role in vascular disease and calcification. Studies in vitro and in animal models suggest that OPG inhibits vascular calcification. Paradoxically however, clinical studies suggest that serum OPG levels increase in association with vascular calcification, coronary artery disease, stroke and future cardiovascular events. This has led to an extensive debate on the potential of OPG as a biomarker of vascular disease. However the exact significance and mechanisms by which this bone-regulatory protein influences cardiovascular pathophysiology is still unclear. The need for a more complete picture is being addressed in increasing valuable research indicating OPG as not only a marker but also a mediator of vascular pathology modulating osteogenic, inflammatory and apoptotic responses. By integrating the results of recent experimental research, animal models and clinical studies, this review summarises the present understanding of the role of OPG in vascular disease and calcification.

PubMed Disclaimer

Figures

Figure 1
Figure 1
The origin of increased OPG. The production of OPG in VSMC and endothelial cells is enhanced by inflammatory cytokines and may reflect endothelial dysfunction. Additionally, the failing myocardium, plaque rupture and other inflamed tissues could contribute to elevated circulating OPG concentrations. LV, left ventricular; MMP, matrix metalloproteases; OPG, osteoprotegerin; VSMC, vascular smooth muscle cells.
Figure 2
Figure 2. OPG as a mediator in vascular disease progression
ALP, alkaline phosphatase; eNOS, endothelial nitric oxide synthase; MMP, matrix metalloproteases; OPG, osteoprotegerin; TRAIL, TNF-related apoptosis-inducing ligand; RANKL, receptor activator of NF-κB ligand; VSMC, vacular smooth muscle cells.
See this image and copyright information in PMC

References

    1. Bagger YZ, Tanko LB, Alexandersen P, et al. Radiographic measure of aorta calcification is a site-specific predictor of bone loss and fracture risk at the hip. J Intern Med. 2006;259:598–605. - PubMed
    1. Hak AE, Pols HA, van Hemert AM, et al. Progression of aortic calcification is associated with metacarpal bone loss during menopause: a population-based longitudinal study. Arterioscler Thromb Vasc Biol. 2000;20:1926–1931. - PubMed
    1. Kiel DP, Kauppila LI, Cupples LA, et al. Bone loss and the progression of abdominal aortic calcification over a 25 year period: the Framingham Heart Study. Calcif Tissue Int. 2001;68:271–276. - PubMed
    1. Schulz E, Arfai K, Liu X, et al. Aortic calcification and the risk of osteoporosis and fractures. J Clin Endocrinol Metab. 2004;89:4246–4253. - PubMed
    1. Tanko LB, Bagger YZ, Christiansen C. Low bone mineral density in the hip as a marker of advanced atherosclerosis in elderly women. Calcif Tissue Int. 2003;73:15–20. - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources